SAT-432 MTD201 Has a Favourable 28-Day Sustained Release Profile Compared to Sandostatin LAR in Healthy Subjects

A double-blind, randomised, single-dose parallel group study was performed to compare the tolerability, pharmacokinetics and pharmacodynamics of MTD201 30 mg octreotide (test product) and Sandostatin LAR 30 mg (reference product) in healthy subjects. MTD201 uses Q-Sphera™ printing technology to prec...

Descripción completa

Detalles Bibliográficos
Autores principales: Seaman, Paul, Damment, Stephen, Bamsey, Katherine, Dryja, Anna, Cook, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552328/
http://dx.doi.org/10.1210/js.2019-SAT-432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552328/
http://dx.doi.org/10.1210/js.2019-SAT-432

Ejemplares similares